PURPOSE: The oligometastatic state is an intermediate state between a malignancy that can be completely eradicated with conventional modalities and one in which a palliative approach is undertaken. Clinically, high rates of @entity5 control are possible with stereotactic ablative radiation therapy (SABR), using precisely targeted, high-dose, low-fraction radiation therapy. However, in @entity320 , virtually all @entity1 develop progression systemically at sites not initially treated with ablative radiation therapy that cannot be managed with conventional chemotherapy and immunotherapy. We have demonstrated in @entity19 that intravenous administration of @entity8310 virus (VSV) expressing defined @entity5 -associated antigens (TAAs) generates systemic immune responses capable of clearing established @entity5 . Therefore, in the  present preclinical study, we tested whether the combination of systemic VSV-mediated antigen delivery and SABR would be effective against @entity66 . METHODS AND MATERIALS: We generated a model of @entity320 in C57BL/6 immunocompetent @entity19 and then used a combination of SABR and systemically administered VSV- @entity2796 viral immunotherapy to treat both @entity262 . RESULTS: Our data showed that SABR generates excellent control or cure of local, clinically detectable, and accessible @entity5 through direct cell ablation. Also, the immunotherapeutic activity of systemically administered VSV- @entity2796 generated T-cell responses that cleared subclinical @entity3 . We also showed that SABR induced weak T-cell-mediated @entity5 responses, which, particularly if boosted by VSV- @entity2796 , might contribute to control of @entity262 . In addition, VSV- @entity2796 therapy alone had significant effects on control of both local and @entity3 . CONCLUSIONS: We have shown in the present preliminary @entity19 study using a single @entity5 model that this approach represents an effective, complementary combination therapy model that addresses the need for both systemic and local control in @entity320 .

Definitive Management of XXXX in a @entity19 Model Using Combined  Ablative Radiation Therapy and  Viral  Immunotherapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2796 :: ('CHEBI:32497', 'Chemical') :: ['TAA'] @entity66 :: ('MESH:D004194', 'Disease') :: ['oligometastatic disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'local tumor', 'tumors'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity8310 :: ('MESH:D054243', 'Disease') :: ['vesicular stomatitis'] @entity262 :: ('MESH:D034721', 'Disease') :: ['local and systemic disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors'] @entity320 :: ('MESH:D008545', 'Disease') :: ['oligometastatic melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['Oligometastatic Melanoma']
